长春瑞滨联合顺铂治疗晚期乳腺癌的临床观察

The Clinical Observation of NVB Combined with DDP for Advanced Breast Cancer

目的:观察长春瑞滨联合顺铂(NP方案)治疗晚期乳腺癌的疗效及不良反应。方法:采用长春瑞滨联合顺铂治疗术后复发或转移性乳腺癌48例,长春瑞滨25mg/m^2,静脉滴注,d_(1,8),顺铂70mg/m^2,静脉滴注,d_2,21天～28天为1周期。结果:全组有效率60.4%,中位生存时间25个月,1、3、5年生存率分别为77.1%、21.8%、5.5%。初治组疗效明显优于复治组(P=0.008);该方案对于既往是否使用蒽环类药物或紫杉醇类药物患者治疗的有效率差异无统计学意义(P>0.05);转移灶1个～2个组和≥3个组治疗有效率差异无统计学意义(P=0.85)。Ⅲ度～Ⅳ度不良反应主要表现为白细胞减少和胃肠道反应。结论:NP方案治疗晚期乳腺癌可获得较好的临床疗效。

Objective： To observe the therapeutic effects and adverse reactions of vinorelbine （NVB） combined with cisplatin （DDP） in the treatment of patients with advanced breast cancer. Methods： 48 patients with recurrent or metastatic breast cancer received chemotherapy of regimen NVB 25mg/m^2 d1 , d8 and DDP 70mg/m^2 d2,21 -28 days as one cycle. Results： The overall effective rate was 60. 4%, the median survival time was 25 months, and the survival rates of 1, 3 and 5 years were 77. 1%, 21.8% and 5. 5% respectively. The efficacy of the group of untreated patients was obviously superior to that of retreated patients （P = 0. 0008 ）. The efficacy was not statistically different between the patients who had received and who had not received previous treatment of anthracycline or taxane （P 〉 0. 05 ）. And the efficacy was not influenced by the number of metastatic lesions （P = 0. 85 ）. Ⅲ-Ⅳdegree of adverse reactions mainly included leucopenia and gastrointestinal reaction. Conclusion： This study shows that the regimen of ＂NP＂ is effective for advanced breast cancer.